NovoSeven is a recombinant factor VIIa (rfVIIa) product marketed by Novo Nordisk. NovoSeven acts as a bypassing agent for patients who have developed inhibitors against fVIII in hemophilia A and fIX in hemophilia B. FVIIa therapy can circumvent the need for fVIII and fIX in the coagulation cascade by directly activating factor X, thereby increasing thrombin levels and formation of fibrin clots.
NovoSeven was originally developed by ZymoGenetics, which was acquired by Bristol-Myers Squibb. Novo Nordisk licensed NovoSeven from ZymoGenetics in 2000, and has marketed it globally since.
LIST OF FIGURES
9 Figure 76: Vonvendi for hemophilia – SWOT analysis
10 Figure 54: Datamonitor Healthcare’s drug assessment summary of NovoEight for hemophilia
12 Figure 55: Datamonitor Healthcare’s drug assessment summary of NovoEight for hemophilia
LIST OF TABLES
6 Table 1: NovoSeven drug profile
7 Table 2: NovoSeven pivotal trial data in hemophilia
13 Table 3: NovoSeven sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2016–25
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726